- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Therapies in Adult B-Cell Malignancies
Authors
Keywords
-
Journal
Biomed Research International
Volume 2015, Issue -, Pages 1-16
Publisher
Hindawi Limited
Online
2015-09-07
DOI
10.1155/2015/217593
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The development of potential antibody-based therapies for myeloma
- (2015) Daniel W. Sherbenou et al. BLOOD REVIEWS
- The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity inCXCR4Wild-typeandCXCR4WHIMmutated Waldenstrom macroglobulinaemia cells
- (2015) Yang Cao et al. BRITISH JOURNAL OF HAEMATOLOGY
- Interleukin-6 as a Therapeutic Target
- (2015) J.-F. Rossi et al. CLINICAL CANCER RESEARCH
- FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
- (2015) B. W. Miller et al. CLINICAL CANCER RESEARCH
- A Comprehensive Immunoreceptor Phosphotyrosine-based Signaling Network Revealed by Reciprocal Protein–Peptide Array Screening
- (2015) Huadong Liu et al. MOLECULAR & CELLULAR PROTEOMICS
- Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
- (2015) Anouk Caraux et al. Oncotarget
- A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
- (2015) Russell T Burke et al. Oncotarget
- The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
- (2015) Liesbeth Bieghs et al. Oncotarget
- Differential Expression of CD200 in B-Cell Neoplasms by Flow Cytometry Can Assist in Diagnosis, Subclassification, and Bone Marrow Staging
- (2014) Pramoda Challagundla et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
- (2014) Y. X. Zhu et al. BLOOD
- Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway
- (2014) Ting Li et al. BMC CANCER
- Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?
- (2014) Inge Marie Svane et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking
- (2014) B Martin-Antonio et al. CELL DEATH AND DIFFERENTIATION
- Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease
- (2014) James O.J. Davies et al. CYTOTHERAPY
- Anti-CD37 antibodies for chronic lymphocytic leukemia
- (2014) Tadeusz Robak et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Lorvotuzumab mertansine: antibody-drug-conjugate for CD56⁺ multiple myeloma
- (2014) Jesus Berdeja Frontiers in Bioscience-Landmark
- Elotuzumab for the treatment of multiple myeloma
- (2014) Philippe Moreau et al. Future Oncology
- Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
- (2014) F. D. Roit et al. HAEMATOLOGICA
- Ligation of human Fc receptor like-2 by monoclonal antibodies down-regulates B-cell receptor-mediated signalling
- (2014) Mahdi Shabani et al. IMMUNOLOGY
- Reprint of: Environments of B cell development
- (2014) Motokazu Tsuneto et al. IMMUNOLOGY LETTERS
- Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE(R)) antibody construct blinatumomab as a potential therapy
- (2014) Z. Zimmerman et al. INTERNATIONAL IMMUNOLOGY
- IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors
- (2014) M Jourdan et al. LEUKEMIA
- T0070907, a PPAR γ Inhibitor, Induced G2/M Arrest Enhances the Effect of Radiation in Human Cervical Cancer Cells Through Mitotic Catastrophe
- (2014) Zhengzhe An et al. Reproductive Sciences
- Targeting BCL2 for the Treatment of Lymphoid Malignancies
- (2014) Mary Ann Anderson et al. SEMINARS IN HEMATOLOGY
- Potential role of daratumumab in the treatment of multiple myeloma
- (2014) Tomer Mark et al. OncoTargets and Therapy
- Driving CAR-Based T-Cell Therapy to Success
- (2014) Bipulendu Jena et al. Current Hematologic Malignancy Reports
- Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways
- (2014) S J Allison et al. Oncogenesis
- Plasticity of γδ T Cells: Impact on the Anti-Tumor Response
- (2014) Virginie Lafont et al. Frontiers in Immunology
- Tumor-Infiltrating γδ T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programing in the Tumor Microenvironment
- (2014) Elena Lo Presti et al. Frontiers in Immunology
- Trial Watch
- (2014) Erika Vacchelli et al. OncoImmunology
- Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook
- (2013) Loretta Sullivan-Chang et al. BIODRUGS
- Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab
- (2013) E. A. Rossi et al. BLOOD
- Immunotherapeutic strategies for relapse control in acute myeloid leukemia
- (2013) Anna Martner et al. BLOOD REVIEWS
- A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701
- (2013) Barbara W. Grant et al. CANCER
- Role of chemokines and their receptors in chronic lymphocytic leukemia
- (2013) Ting-Ting Han et al. CANCER BIOLOGY & THERAPY
- The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer
- (2013) Polina Weitzenfeld et al. CANCER LETTERS
- Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
- (2013) Prithviraj Bose et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma
- (2013) Rogier M. Reijmers et al. FEBS Journal
- Targeting lactate metabolism for cancer therapeutics
- (2013) Joanne R. Doherty et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
- (2013) Luis Fayad et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells
- (2013) Z. Husain et al. JOURNAL OF IMMUNOLOGY
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- (2013) Susan O'Brien et al. LANCET ONCOLOGY
- Tumor glycolysis as a target for cancer therapy: progress and prospects
- (2013) Shanmugasundaram Ganapathy-Kanniappan et al. Molecular Cancer
- Paradoxical Regulation of Hypoxia Inducible Factor-1α (HIF-1α) by Histone Deacetylase Inhibitor in Diffuse Large B-Cell Lymphoma
- (2013) Savita Bhalla et al. PLoS One
- Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005
- (2012) Bruno Paiva et al. AMERICAN JOURNAL OF PATHOLOGY
- Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium
- (2012) B. M. Birmann et al. BLOOD
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Novel molecular mechanisms of antitumor action of dichloroacetate against T cell lymphoma: Implication of altered glucose metabolism, pH homeostasis and cell survival regulation
- (2012) Ajay Kumar et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Phase I Study of Atacicept in Relapsed/Refractory Multiple Myeloma (MM) and Waldenström's Macroglobulinemia
- (2012) Jean-François Rossi Clinical Lymphoma Myeloma & Leukemia
- Role of ITAM signaling module in signal integration
- (2012) Jelena S Bezbradica et al. CURRENT OPINION IN IMMUNOLOGY
- The establishment of the plasma cell survival niche in the bone marrow
- (2012) Van T. Chu et al. IMMUNOLOGICAL REVIEWS
- Case Report: Sodium dichloroacetate (DCA) inhibition of the “Warburg Effect” in a human cancer patient: complete response in non-Hodgkin’s lymphoma after disease progression with rituximab-CHOP
- (2012) Stephen B. Strum et al. JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
- The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
- (2012) Kenneth C. Anderson JOURNAL OF CLINICAL ONCOLOGY
- Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
- (2012) Adrian Wiestner JOURNAL OF CLINICAL ONCOLOGY
- The secrets of the bone marrow niche: Metabolic priming for AML
- (2012) Rushdia Z Yusuf et al. NATURE MEDICINE
- The growing complexity of HIF-1α’s role in tumorigenesis: DNA repair and beyond
- (2012) N Rohwer et al. ONCOGENE
- Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients
- (2012) Caroline Rousseau et al. TUMOR BIOLOGY
- Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
- (2012) Henrik E Mei et al. ARTHRITIS RESEARCH & THERAPY
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- Proteasome inhibitors in cancer therapy
- (2011) Lisa J. Crawford et al. Journal of Cell Communication and Signaling
- Immunophenotyping in multiple myeloma and related plasma cell disorders
- (2010) Shaji Kumar et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases
- (2010) Nichola Cooper et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma
- (2010) J. J. Hwang et al. CLINICAL CANCER RESEARCH
- T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody
- (2010) M. S. Braza et al. HAEMATOLOGICA
- Rituximab-Associated Infections
- (2010) Juan C. Gea-Banacloche SEMINARS IN HEMATOLOGY
- High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma
- (2010) MAJDA SAIFI et al. Experimental and Therapeutic Medicine
- Atacicept: targeting B cells in multiple sclerosis
- (2010) Hans-Peter Hartung et al. Therapeutic Advances in Neurological Disorders
- Long-Term Effects of Rituximab in Rheumatoid Arthritis
- (2009) Luca Quartuccio et al. Annals of the New York Academy of Sciences
- Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
- (2009) J-F Rossi et al. BRITISH JOURNAL OF CANCER
- Anti-CD20 monoclonal antibodies: historical and future perspectives
- (2009) S. H. Lim et al. HAEMATOLOGICA
- Large scale expansion of Vγ9Vδ2 T lymphocytes from human peripheral blood mononuclear cells after a positive selection using MACS “TCR γ/δ + T cell isolation kit”
- (2009) Samuel Salot et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Mimicking the BH3 domain to kill cancer cells
- (2009) T Ni Chonghaile et al. ONCOGENE
- Milatuzumab: a promising new agent for the treatment of lymphoid malignancies
- (2008) Tomer Mark et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study
- (2008) Guillaume Cartron et al. JOURNAL OF CLINICAL ONCOLOGY
- T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
- (2007) Pierre Raynaud et al. HUMAN PATHOLOGY
- High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial
- (2007) Danielle Canioni et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started